ABL1 is an inclusion eligibility criterion in 1 clinical trial for histiocytic and dendritic cell neoplasm, of which 1 is open and 0 are closed. Of the trial that contains ABL1 status and histiocytic and dendritic cell neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

AFF1 is an inclusion eligibility criterion in 1 clinical trial for histiocytic and dendritic cell neoplasm, of which 1 is open and 0 are closed. Of the trial that contains AFF1 status and histiocytic and dendritic cell neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

AKT1 is altered in 0.75% of histiocytic and dendritic cell neoplasm patients [2].

AKT1 is an inclusion eligibility criterion in 1 clinical trial for histiocytic and dendritic cell neoplasm, of which 1 is open and 0 are closed. Of the trial that contains AKT1 status and histiocytic and dendritic cell neoplasm as inclusion criteria, 1 is phase 2 (1 open) [3].

AKT2 is an inclusion eligibility criterion in 1 clinical trial for histiocytic and dendritic cell neoplasm, of which 1 is open and 0 are closed. Of the trial that contains AKT2 status and histiocytic and dendritic cell neoplasm as inclusion criteria, 1 is phase 2 (1 open) [3].

AKT3 is an inclusion eligibility criterion in 1 clinical trial for histiocytic and dendritic cell neoplasm, of which 1 is open and 0 are closed. Of the trial that contains AKT3 status and histiocytic and dendritic cell neoplasm as inclusion criteria, 1 is phase 2 (1 open) [3].

ALK is altered in 0.75% of histiocytic and dendritic cell neoplasm patients [2].

ALK is an inclusion eligibility criterion in 1 clinical trial for histiocytic and dendritic cell neoplasm, of which 1 is open and 0 are closed. Of the trial that contains ALK status and histiocytic and dendritic cell neoplasm as inclusion criteria, 1 is phase 2 (1 open) [3].

ARAF is altered in 1.57% of histiocytic and dendritic cell neoplasm patients [2].

ARAF is an inclusion eligibility criterion in 2 clinical trials for histiocytic and dendritic cell neoplasm, of which 1 is open and 1 is closed. Of the trials that contain ARAF status and histiocytic and dendritic cell neoplasm as inclusion criteria, 2 are phase 2 (1 open) [3].

ASXL1 is altered in 4.3% of histiocytic and dendritic cell neoplasm patients [2].

ASXL1 is an inclusion eligibility criterion in 1 clinical trial for histiocytic and dendritic cell neoplasm, of which 1 is open and 0 are closed. Of the trial that contains ASXL1 status and histiocytic and dendritic cell neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

BCR is altered in 0.48% of histiocytic and dendritic cell neoplasm patients [2].

BCR is an inclusion eligibility criterion in 1 clinical trial for histiocytic and dendritic cell neoplasm, of which 1 is open and 0 are closed. Of the trial that contains BCR status and histiocytic and dendritic cell neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

BRAF is altered in 24.09% of histiocytic and dendritic cell neoplasm patients [2].

BRAF is an inclusion eligibility criterion in 2 clinical trials for histiocytic and dendritic cell neoplasm, of which 1 is open and 1 is closed. Of the trials that contain BRAF status and histiocytic and dendritic cell neoplasm as inclusion criteria, 2 are phase 2 (1 open) [3].

CCND1 is an inclusion eligibility criterion in 1 clinical trial for histiocytic and dendritic cell neoplasm, of which 1 is open and 0 are closed. Of the trial that contains CCND1 status and histiocytic and dendritic cell neoplasm as inclusion criteria, 1 is phase 2 (1 open) [3].

CCND2 is an inclusion eligibility criterion in 1 clinical trial for histiocytic and dendritic cell neoplasm, of which 1 is open and 0 are closed. Of the trial that contains CCND2 status and histiocytic and dendritic cell neoplasm as inclusion criteria, 1 is phase 2 (1 open) [3].

CCND3 is altered in 0.39% of histiocytic and dendritic cell neoplasm patients [2].

CCND3 is an inclusion eligibility criterion in 1 clinical trial for histiocytic and dendritic cell neoplasm, of which 1 is open and 0 are closed. Of the trial that contains CCND3 status and histiocytic and dendritic cell neoplasm as inclusion criteria, 1 is phase 2 (1 open) [3].

CCNE1 is an inclusion eligibility criterion in 1 clinical trial for histiocytic and dendritic cell neoplasm, of which 1 is open and 0 are closed. Of the trial that contains CCNE1 status and histiocytic and dendritic cell neoplasm as inclusion criteria, 1 is phase 2 (1 open) [3].

CCNE2 is an inclusion eligibility criterion in 1 clinical trial for histiocytic and dendritic cell neoplasm, of which 1 is open and 0 are closed. Of the trial that contains CCNE2 status and histiocytic and dendritic cell neoplasm as inclusion criteria, 1 is phase 2 (1 open) [3].

CDK2 is an inclusion eligibility criterion in 1 clinical trial for histiocytic and dendritic cell neoplasm, of which 1 is open and 0 are closed. Of the trial that contains CDK2 status and histiocytic and dendritic cell neoplasm as inclusion criteria, 1 is phase 2 (1 open) [3].

CDK4 is altered in 0.4% of histiocytic and dendritic cell neoplasm patients [2].

CDK4 is an inclusion eligibility criterion in 1 clinical trial for histiocytic and dendritic cell neoplasm, of which 1 is open and 0 are closed. Of the trial that contains CDK4 status and histiocytic and dendritic cell neoplasm as inclusion criteria, 1 is phase 2 (1 open) [3].

CDK6 is an inclusion eligibility criterion in 1 clinical trial for histiocytic and dendritic cell neoplasm, of which 1 is open and 0 are closed. Of the trial that contains CDK6 status and histiocytic and dendritic cell neoplasm as inclusion criteria, 1 is phase 2 (1 open) [3].

CDKN1A is an inclusion eligibility criterion in 1 clinical trial for histiocytic and dendritic cell neoplasm, of which 1 is open and 0 are closed. Of the trial that contains CDKN1A status and histiocytic and dendritic cell neoplasm as inclusion criteria, 1 is phase 2 (1 open) [3].

CDKN1B is altered in 1.57% of histiocytic and dendritic cell neoplasm patients [2].

CDKN1B is an inclusion eligibility criterion in 1 clinical trial for histiocytic and dendritic cell neoplasm, of which 1 is open and 0 are closed. Of the trial that contains CDKN1B status and histiocytic and dendritic cell neoplasm as inclusion criteria, 1 is phase 2 (1 open) [3].

CDKN2A is altered in 3.66% of histiocytic and dendritic cell neoplasm patients [2].

CDKN2A is an inclusion eligibility criterion in 1 clinical trial for histiocytic and dendritic cell neoplasm, of which 1 is open and 0 are closed. Of the trial that contains CDKN2A status and histiocytic and dendritic cell neoplasm as inclusion criteria, 1 is phase 2 (1 open) [3].

CRKL is an inclusion eligibility criterion in 3 clinical trials for histiocytic and dendritic cell neoplasm, of which 2 are open and 1 is closed. Of the trials that contain CRKL status and histiocytic and dendritic cell neoplasm as inclusion criteria, 3 are phase 2 (2 open) [3].

DEK is an inclusion eligibility criterion in 1 clinical trial for histiocytic and dendritic cell neoplasm, of which 1 is open and 0 are closed. Of the trial that contains DEK status and histiocytic and dendritic cell neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

ELL is an inclusion eligibility criterion in 1 clinical trial for histiocytic and dendritic cell neoplasm, of which 1 is open and 0 are closed. Of the trial that contains ELL status and histiocytic and dendritic cell neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

EZH2 is altered in 0.75% of histiocytic and dendritic cell neoplasm patients [2].

EZH2 is an inclusion eligibility criterion in 1 clinical trial for histiocytic and dendritic cell neoplasm, of which 1 is open and 0 are closed. Of the trial that contains EZH2 status and histiocytic and dendritic cell neoplasm as inclusion criteria, 1 is phase 2 (1 open) [3].

FGFR1 is an inclusion eligibility criterion in 1 clinical trial for histiocytic and dendritic cell neoplasm, of which 1 is open and 0 are closed. Of the trial that contains FGFR1 status and histiocytic and dendritic cell neoplasm as inclusion criteria, 1 is phase 2 (1 open) [3].

FGFR2 is altered in 0.38% of histiocytic and dendritic cell neoplasm patients [2].

FGFR2 is an inclusion eligibility criterion in 1 clinical trial for histiocytic and dendritic cell neoplasm, of which 1 is open and 0 are closed. Of the trial that contains FGFR2 status and histiocytic and dendritic cell neoplasm as inclusion criteria, 1 is phase 2 (1 open) [3].

FGFR3 is altered in 1.49% of histiocytic and dendritic cell neoplasm patients [2].

FGFR3 is an inclusion eligibility criterion in 1 clinical trial for histiocytic and dendritic cell neoplasm, of which 1 is open and 0 are closed. Of the trial that contains FGFR3 status and histiocytic and dendritic cell neoplasm as inclusion criteria, 1 is phase 2 (1 open) [3].

FGFR4 is altered in 0.39% of histiocytic and dendritic cell neoplasm patients [2].

FGFR4 is an inclusion eligibility criterion in 1 clinical trial for histiocytic and dendritic cell neoplasm, of which 1 is open and 0 are closed. Of the trial that contains FGFR4 status and histiocytic and dendritic cell neoplasm as inclusion criteria, 1 is phase 2 (1 open) [3].

FLT3 is altered in 0.74% of histiocytic and dendritic cell neoplasm patients [2].

FLT3 is an inclusion eligibility criterion in 1 clinical trial for histiocytic and dendritic cell neoplasm, of which 1 is open and 0 are closed. Of the trial that contains FLT3 status and histiocytic and dendritic cell neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

HRAS is an inclusion eligibility criterion in 2 clinical trials for histiocytic and dendritic cell neoplasm, of which 1 is open and 1 is closed. Of the trials that contain HRAS status and histiocytic and dendritic cell neoplasm as inclusion criteria, 2 are phase 2 (1 open) [3].

KMT2A is altered in 1.54% of histiocytic and dendritic cell neoplasm patients [2].

KMT2A is an inclusion eligibility criterion in 1 clinical trial for histiocytic and dendritic cell neoplasm, of which 1 is open and 0 are closed. Of the trial that contains KMT2A status and histiocytic and dendritic cell neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

KRAS is altered in 6.57% of histiocytic and dendritic cell neoplasm patients [2].

KRAS is an inclusion eligibility criterion in 2 clinical trials for histiocytic and dendritic cell neoplasm, of which 1 is open and 1 is closed. Of the trials that contain KRAS status and histiocytic and dendritic cell neoplasm as inclusion criteria, 2 are phase 2 (1 open) [3].

MAP2K1 is altered in 12.3% of histiocytic and dendritic cell neoplasm patients [2].

MAP2K1 is an inclusion eligibility criterion in 2 clinical trials for histiocytic and dendritic cell neoplasm, of which 1 is open and 1 is closed. Of the trials that contain MAP2K1 status and histiocytic and dendritic cell neoplasm as inclusion criteria, 2 are phase 2 (1 open) [3].

MAP2K2 is an inclusion eligibility criterion in 2 clinical trials for histiocytic and dendritic cell neoplasm, of which 1 is open and 1 is closed. Of the trials that contain MAP2K2 status and histiocytic and dendritic cell neoplasm as inclusion criteria, 2 are phase 2 (1 open) [3].

MAP2K4 is an inclusion eligibility criterion in 2 clinical trials for histiocytic and dendritic cell neoplasm, of which 1 is open and 1 is closed. Of the trials that contain MAP2K4 status and histiocytic and dendritic cell neoplasm as inclusion criteria, 2 are phase 2 (1 open) [3].

MAP3K1 is altered in 0.79% of histiocytic and dendritic cell neoplasm patients [2].

MAP3K1 is an inclusion eligibility criterion in 2 clinical trials for histiocytic and dendritic cell neoplasm, of which 1 is open and 1 is closed. Of the trials that contain MAP3K1 status and histiocytic and dendritic cell neoplasm as inclusion criteria, 2 are phase 2 (1 open) [3].

MAPK1 is an inclusion eligibility criterion in 2 clinical trials for histiocytic and dendritic cell neoplasm, of which 1 is open and 1 is closed. Of the trials that contain MAPK1 status and histiocytic and dendritic cell neoplasm as inclusion criteria, 2 are phase 2 (1 open) [3].

MECOM is an inclusion eligibility criterion in 1 clinical trial for histiocytic and dendritic cell neoplasm, of which 1 is open and 0 are closed. Of the trial that contains MECOM status and histiocytic and dendritic cell neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

MLF1 is an inclusion eligibility criterion in 1 clinical trial for histiocytic and dendritic cell neoplasm, of which 1 is open and 0 are closed. Of the trial that contains MLF1 status and histiocytic and dendritic cell neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

MLLT1 is an inclusion eligibility criterion in 1 clinical trial for histiocytic and dendritic cell neoplasm, of which 1 is open and 0 are closed. Of the trial that contains MLLT1 status and histiocytic and dendritic cell neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

MLLT10 is an inclusion eligibility criterion in 1 clinical trial for histiocytic and dendritic cell neoplasm, of which 1 is open and 0 are closed. Of the trial that contains MLLT10 status and histiocytic and dendritic cell neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

MLLT3 is an inclusion eligibility criterion in 1 clinical trial for histiocytic and dendritic cell neoplasm, of which 1 is open and 0 are closed. Of the trial that contains MLLT3 status and histiocytic and dendritic cell neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

MLLT4 is an inclusion eligibility criterion in 1 clinical trial for histiocytic and dendritic cell neoplasm, of which 1 is open and 0 are closed. Of the trial that contains MLLT4 status and histiocytic and dendritic cell neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

MTOR is altered in 1.18% of histiocytic and dendritic cell neoplasm patients [2].

MTOR is an inclusion eligibility criterion in 1 clinical trial for histiocytic and dendritic cell neoplasm, of which 1 is open and 0 are closed. Of the trial that contains MTOR status and histiocytic and dendritic cell neoplasm as inclusion criteria, 1 is phase 2 (1 open) [3].

NF1 is altered in 2.33% of histiocytic and dendritic cell neoplasm patients [2].

NF1 is an inclusion eligibility criterion in 2 clinical trials for histiocytic and dendritic cell neoplasm, of which 1 is open and 1 is closed. Of the trials that contain NF1 status and histiocytic and dendritic cell neoplasm as inclusion criteria, 2 are phase 2 (1 open) [3].

NPM1 is an inclusion eligibility criterion in 1 clinical trial for histiocytic and dendritic cell neoplasm, of which 1 is open and 0 are closed. Of the trial that contains NPM1 status and histiocytic and dendritic cell neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

NRAS is altered in 3.69% of histiocytic and dendritic cell neoplasm patients [2].

NRAS is an inclusion eligibility criterion in 2 clinical trials for histiocytic and dendritic cell neoplasm, of which 1 is open and 1 is closed. Of the trials that contain NRAS status and histiocytic and dendritic cell neoplasm as inclusion criteria, 2 are phase 2 (1 open) [3].

NRIP3 is an inclusion eligibility criterion in 1 clinical trial for histiocytic and dendritic cell neoplasm, of which 1 is open and 0 are closed. Of the trial that contains NRIP3 status and histiocytic and dendritic cell neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

NTRK1 is altered in 0.4% of histiocytic and dendritic cell neoplasm patients [2].

NTRK1 is an inclusion eligibility criterion in 1 clinical trial for histiocytic and dendritic cell neoplasm, of which 1 is open and 0 are closed. Of the trial that contains NTRK1 status and histiocytic and dendritic cell neoplasm as inclusion criteria, 1 is phase 2 (1 open) [3].

NTRK2 is an inclusion eligibility criterion in 1 clinical trial for histiocytic and dendritic cell neoplasm, of which 1 is open and 0 are closed. Of the trial that contains NTRK2 status and histiocytic and dendritic cell neoplasm as inclusion criteria, 1 is phase 2 (1 open) [3].

NTRK3 is altered in 0.79% of histiocytic and dendritic cell neoplasm patients [2].

NTRK3 is an inclusion eligibility criterion in 1 clinical trial for histiocytic and dendritic cell neoplasm, of which 1 is open and 0 are closed. Of the trial that contains NTRK3 status and histiocytic and dendritic cell neoplasm as inclusion criteria, 1 is phase 2 (1 open) [3].

NUP214 is altered in 1.28% of histiocytic and dendritic cell neoplasm patients [2].

NUP214 is an inclusion eligibility criterion in 1 clinical trial for histiocytic and dendritic cell neoplasm, of which 1 is open and 0 are closed. Of the trial that contains NUP214 status and histiocytic and dendritic cell neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

PDGFRA is altered in 0.37% of histiocytic and dendritic cell neoplasm patients [2].

PDGFRA is an inclusion eligibility criterion in 1 clinical trial for histiocytic and dendritic cell neoplasm, of which 1 is open and 0 are closed. Of the trial that contains PDGFRA status and histiocytic and dendritic cell neoplasm as inclusion criteria, 1 is phase 2 (1 open) [3].

PIK3CA is altered in 0.74% of histiocytic and dendritic cell neoplasm patients [2].

PIK3CA is an inclusion eligibility criterion in 1 clinical trial for histiocytic and dendritic cell neoplasm, of which 1 is open and 0 are closed. Of the trial that contains PIK3CA status and histiocytic and dendritic cell neoplasm as inclusion criteria, 1 is phase 2 (1 open) [3].

PIK3CG is an inclusion eligibility criterion in 1 clinical trial for histiocytic and dendritic cell neoplasm, of which 1 is open and 0 are closed. Of the trial that contains PIK3CG status and histiocytic and dendritic cell neoplasm as inclusion criteria, 1 is phase 2 (1 open) [3].

PIK3R1 is an inclusion eligibility criterion in 1 clinical trial for histiocytic and dendritic cell neoplasm, of which 1 is open and 0 are closed. Of the trial that contains PIK3R1 status and histiocytic and dendritic cell neoplasm as inclusion criteria, 1 is phase 2 (1 open) [3].

PIK3R2 is an inclusion eligibility criterion in 1 clinical trial for histiocytic and dendritic cell neoplasm, of which 1 is open and 0 are closed. Of the trial that contains PIK3R2 status and histiocytic and dendritic cell neoplasm as inclusion criteria, 1 is phase 2 (1 open) [3].

PTEN is altered in 0.74% of histiocytic and dendritic cell neoplasm patients [2].

PTEN is an inclusion eligibility criterion in 1 clinical trial for histiocytic and dendritic cell neoplasm, of which 1 is open and 0 are closed. Of the trial that contains PTEN status and histiocytic and dendritic cell neoplasm as inclusion criteria, 1 is phase 2 (1 open) [3].

RAF1 is altered in 0.4% of histiocytic and dendritic cell neoplasm patients [2].

RAF1 is an inclusion eligibility criterion in 2 clinical trials for histiocytic and dendritic cell neoplasm, of which 1 is open and 1 is closed. Of the trials that contain RAF1 status and histiocytic and dendritic cell neoplasm as inclusion criteria, 2 are phase 2 (1 open) [3].

RB1 is altered in 0.75% of histiocytic and dendritic cell neoplasm patients [2].

RB1 is an inclusion eligibility criterion in 1 clinical trial for histiocytic and dendritic cell neoplasm, of which 1 is open and 0 are closed. Of the trial that contains RB1 status and histiocytic and dendritic cell neoplasm as inclusion criteria, 1 is phase 2 (1 open) [3].

RICTOR is an inclusion eligibility criterion in 1 clinical trial for histiocytic and dendritic cell neoplasm, of which 1 is open and 0 are closed. Of the trial that contains RICTOR status and histiocytic and dendritic cell neoplasm as inclusion criteria, 1 is phase 2 (1 open) [3].

ROS1 is altered in 1.58% of histiocytic and dendritic cell neoplasm patients [2].

ROS1 is an inclusion eligibility criterion in 1 clinical trial for histiocytic and dendritic cell neoplasm, of which 1 is open and 0 are closed. Of the trial that contains ROS1 status and histiocytic and dendritic cell neoplasm as inclusion criteria, 1 is phase 2 (1 open) [3].

RPN1 is an inclusion eligibility criterion in 1 clinical trial for histiocytic and dendritic cell neoplasm, of which 1 is open and 0 are closed. Of the trial that contains RPN1 status and histiocytic and dendritic cell neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

RPTOR is an inclusion eligibility criterion in 1 clinical trial for histiocytic and dendritic cell neoplasm, of which 1 is open and 0 are closed. Of the trial that contains RPTOR status and histiocytic and dendritic cell neoplasm as inclusion criteria, 1 is phase 2 (1 open) [3].

RUNX1 is altered in 0.78% of histiocytic and dendritic cell neoplasm patients [2].

RUNX1 is an inclusion eligibility criterion in 1 clinical trial for histiocytic and dendritic cell neoplasm, of which 1 is open and 0 are closed. Of the trial that contains RUNX1 status and histiocytic and dendritic cell neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

SMARCA4 is altered in 0.79% of histiocytic and dendritic cell neoplasm patients [2].

SMARCA4 is an inclusion eligibility criterion in 1 clinical trial for histiocytic and dendritic cell neoplasm, of which 1 is open and 0 are closed. Of the trial that contains SMARCA4 status and histiocytic and dendritic cell neoplasm as inclusion criteria, 1 is phase 2 (1 open) [3].

SMARCB1 is an inclusion eligibility criterion in 1 clinical trial for histiocytic and dendritic cell neoplasm, of which 1 is open and 0 are closed. Of the trial that contains SMARCB1 status and histiocytic and dendritic cell neoplasm as inclusion criteria, 1 is phase 2 (1 open) [3].

SRC is an inclusion eligibility criterion in 2 clinical trials for histiocytic and dendritic cell neoplasm, of which 1 is open and 1 is closed. Of the trials that contain SRC status and histiocytic and dendritic cell neoplasm as inclusion criteria, 2 are phase 2 (1 open) [3].

TP53 is altered in 1.09% of histiocytic and dendritic cell neoplasm patients [2].

TP53 is an inclusion eligibility criterion in 1 clinical trial for histiocytic and dendritic cell neoplasm, of which 1 is open and 0 are closed. Of the trial that contains TP53 status and histiocytic and dendritic cell neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

TSC1 is altered in 0.79% of histiocytic and dendritic cell neoplasm patients [2].

TSC1 is an inclusion eligibility criterion in 1 clinical trial for histiocytic and dendritic cell neoplasm, of which 1 is open and 0 are closed. Of the trial that contains TSC1 status and histiocytic and dendritic cell neoplasm as inclusion criteria, 1 is phase 2 (1 open) [3].

TSC2 is altered in 1.95% of histiocytic and dendritic cell neoplasm patients [2].

TSC2 is an inclusion eligibility criterion in 1 clinical trial for histiocytic and dendritic cell neoplasm, of which 1 is open and 0 are closed. Of the trial that contains TSC2 status and histiocytic and dendritic cell neoplasm as inclusion criteria, 1 is phase 2 (1 open) [3].